Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("GATELL, Jose M")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 117

  • Page / 5
Export

Selection :

  • and

Aiming for the long term: focus on the individualGATELL, Jose M.International journal of STD & AIDS. 2009, Vol 20, issn 0956-4624, 21 p., SUP2Serial Issue

When and why to start antiretroviral therapy?GATELL, Jose M.Journal of antimicrobial chemotherapy (Print). 2010, Vol 65, Num 3, pp 383-385, issn 0305-7453, 3 p.Article

Initiating and maintaining HAART - aiming for the long term in treatment-naïve patientsBEHRENS, G.International journal of STD & AIDS. 2009, Vol 20, pp 7-11, issn 0956-4624, 5 p., SUP2Article

Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplificationMARTINEZ, Esteban; GATELL, Jose M.AIDS (London). 2007, Vol 21, Num 13, pp 1829-1830, issn 0269-9370, 2 p.Article

Considering the individual - principles of treatment choiceWATERS, L.International journal of STD & AIDS. 2009, Vol 20, pp 2-6, issn 0956-4624, 5 p., SUP2Article

Understanding protease inhibitor resistance - aiming for the long term in treatment-experienced patientsGERETTI, A. M.International journal of STD & AIDS. 2009, Vol 20, pp 12-17, issn 0956-4624, 6 p., SUP2Article

Considerations about the value of sonography for the measurement of regional body fatMARTINEZ, Esteban; MILINKOVIC, Ana; BIANCHI, Luis et al.AIDS (London). 2006, Vol 20, Num 3, pp 465-466, issn 0269-9370, 2 p.Article

HIV-1 Integrase Inhibitor Resistance and Its Clinical ImplicationsBLANCO, Jose-Luis; VARGHESE, Vici; RHEE, Soo-Yon et al.The Journal of infectious diseases. 2011, Vol 203, Num 9, pp 1204-1214, issn 0022-1899, 11 p.Article

Sonographic assessment of regional fat in HIV-1-infected peopleMARTINEZ, Esteban; BIANCHI, Luis; GARCIA-VIEJO, Miguel Angel et al.Lancet (British edition). 2000, Vol 356, Num 9239, pp 1412-1413, issn 0140-6736Article

Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapyMARTINEZ, Esteban; TUSET, Montserrat; MILINKOVIC, Ana et al.Antiviral therapy (London). 2004, Vol 9, Num 5, pp 649-663, issn 1359-6535, 15 p.Article

Lipodystrophy syndrome in patients with HIV infection : Quality of life issuesMARTINEZ, Esteban; GARCIA-VIEJO, Miguel A; BLANCH, Jordi et al.Drug safety. 2001, Vol 24, Num 3, pp 157-166, issn 0114-5916Article

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsERON, Joseph J; COOPER, David A; LOUTFY, Mona R et al.Lancet. Infectious diseases (print). 2013, Vol 13, Num 7, pp 587-596, issn 1473-3099, 10 p.Article

The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 AntigensGOMEZ, Carmen Elena; NAJERA, José Luis; GUARDO, Alberto C et al.Journal of virology. 2011, Vol 85, Num 21, pp 11468-11478, issn 0022-538X, 11 p.Article

Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strataREEKIE, Joanne; GATELL, Jose M; YUST, Israel et al.AIDS (London). 2011, Vol 25, Num 18, pp 2259-2268, issn 0269-9370, 10 p.Article

Randomized Trial Comparing Pegylated Interferon α-2b Versus Pegylated Interferon α-2a, Both Plus Ribavirin, to Treat Chronic Hepatitis C in Human Immunodeficiency Virus PatientsLAGUNO, Montserrat; CIFUENTES, Carmen; VILLALONGA, Concha et al.Hepatology (Baltimore, Md.). 2009, Vol 49, Num 1, pp 22-31, issn 0270-9139, 10 p.Article

Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapySCHACKER, Timothy W; NGUYEN, Phuong L; HAASE, Ashley T et al.The Journal of infectious diseases. 2002, Vol 186, Num 8, pp 1092-1097, issn 0022-1899, 6 p.Article

Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection : the Scan StudyGARCIA, Felipe; KNOBEL, Hernando; CRUCETA, Anna et al.AIDS (London). 2000, Vol 14, Num 16, pp 2485-2494, issn 0269-9370Article

Effect of Vancomycin Minimal Inhibitory Concentration on the Outcome of Methicillin-Susceptible Staphylococcus aureus EndocarditisCERVERA, Carlos; CASTANEDA, Ximena; NINOT, Salvador et al.Clinical infectious diseases. 2014, Vol 58, Num 12, pp 1668-1675, issn 1058-4838, 8 p.Article

When and how to use maraviroc in HIV-infected patientsSORIANO, Vincent; PERNO, Carlo-Federico; KAISER, Rolf et al.AIDS (London). 2009, Vol 23, Num 18, pp 2377-2385, issn 0269-9370, 9 p.Article

Changes over time in risk of initial virological failure of combination antiretroviral therapy : A multicohort analysis, 1996 to 2002LAMPE, Fiona C; GATELL, Jose M; KRENTZ, Hartmut B et al.Archives of internal medicine (1960). 2006, Vol 166, Num 5, pp 521-528, issn 0003-9926, 8 p.Article

Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panelHAMMER, Scott M; SAAG, Michael S; GATELL, Jose M et al.JAMA, the journal of the American Medical Association. 2006, Vol 296, Num 7, pp 827-843, issn 0098-7484, 17 p.Article

Treatment for adult HIV infection: 2004 Recommendations of the International AIDS Society-USA PanelYENI, Patrick G; HAMMER, Scott M; KATZENSTEIN, David A et al.JAMA, the journal of the American Medical Association. 2004, Vol 292, Num 2, pp 251-265, issn 0098-7484, 15 p.Article

High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/μl and opportunistic diseases: the EfaVIP study (Efavirenz in Very Immunosuppressed Patients)ARRIBAS, Jose R; PULIDO, Federico; DEL PALACIO, Angel et al.AIDS (London). 2002, Vol 16, Num 11, pp 1554-1556, issn 0269-9370Article

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)GARCIA, Felipe; DE QUIROS, Juan Carlos Lopez Bernaldo; CONDE, Matilde Sánchez et al.Vaccine. 2011, Vol 29, Num 46, pp 8309-8316, issn 0264-410X, 8 p.Article

Antiretroviral Treatment of Adult HIV Infection : 2008 Recommendations of the International AIDS Society-USA PanelHAMMER, Scott M; ERON, Joseph J; JACOBSEN, Donna M et al.JAMA, the journal of the American Medical Association. 2008, Vol 300, Num 5, pp 555-570, issn 0098-7484, 16 p.Article

  • Page / 5